公开(公告)号：US20250066422A1

公开(公告)日：2025-02-27

申请号：US18936387

申请日：2024-11-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Steffen WALTER ,  Jens FRITSCHE ,  Colette SONG ,  Harpreet SINGH

IPC: C07K7/08 ,  A61K35/17 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/06 ,  C07K14/725 ,  C12N5/0783 ,  C12N9/64

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

公开(公告)号：US20250064937A1

公开(公告)日：2025-02-27

申请号：US18821068

申请日：2024-08-30

Applicant: ModernaTX, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Sayda M. ELBASHIR

IPC: A61K47/18 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/19 ,  A61K38/48 ,  A61K47/22 ,  A61K47/28 ,  A61K48/00 ,  C07K14/535 ,  C12N9/64 ,  C12N15/67 ,  C12N15/87

Abstract: Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.

公开(公告)号：USRE50288E1

公开(公告)日：2025-02-04

申请号：US18153894

申请日：2023-01-12

Applicant: UNIQURE BIOPHARMA B.V.

Inventor： Paolo Simioni

IPC: A61P7/04 ,  A61K38/48 ,  C12N9/64

Abstract: Disclosed are a modified FIX (factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.

公开(公告)号：US12207628B2

公开(公告)日：2025-01-28

申请号：US17129706

申请日：2020-12-21

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lynn Macdonald ,  Sean Stevens ,  Andrew J. Murphy ,  Margaret Karow

IPC: A01K67/00 ,  A01K67/0275 ,  A01K67/0278 ,  B60H1/32 ,  C07K16/22 ,  C07K16/28 ,  C07K16/40 ,  C07K16/46 ,  C12N9/64 ,  C12N15/85

Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.

公开(公告)号：US20250018062A1

公开(公告)日：2025-01-16

申请号：US18760652

申请日：2024-07-01

Applicant: Moderna TX, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Justin GUILD

IPC: A61K48/00 ,  A61K9/127 ,  A61K9/14 ,  A61K9/51 ,  A61K31/7115 ,  A61K38/00 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/45 ,  A61K38/48 ,  A61K47/54 ,  C07H21/02 ,  C07K14/005 ,  C07K14/435 ,  C07K14/47 ,  C07K14/475 ,  C07K14/485 ,  C07K14/495 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K16/00 ,  C07K16/28 ,  C07K16/40 ,  C12N9/00 ,  C12N9/02 ,  C12N9/10 ,  C12N9/12 ,  C12N9/16 ,  C12N9/24 ,  C12N9/42 ,  C12N9/64 ,  C12N9/68 ,  C12N9/88 ,  C12N15/11 ,  C12N15/52 ,  C12N15/85 ,  C12N15/87 ,  C12P13/04 ,  C12P21/00

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US20250011828A1

公开(公告)日：2025-01-09

申请号：US18886925

申请日：2024-09-16

Applicant: Nobell Foods, Inc.

Inventor： Viviane LANQUAR ,  Magi EL-RICHANI ,  Leyla HATHWAIK ,  Yaxin WANG

IPC: C12P21/06 ,  A23C20/00 ,  A23J3/10 ,  C07K14/47 ,  C12N9/64

Abstract: Provided herein are compositions and methods for producing milk proteins, which allow for safe, sustainable and humane production of milk proteins for commercial use, such as use in food compositions. The disclosure provides recombinant fusion proteins comprising at least first protein and a second protein, wherein at least one of the first protein and the second protein is a milk protein, or fragment thereof. The disclosure also provides methods for producing the recombinant fusions proteins, and food compositions comprising the same.

公开(公告)号：US20240409888A1

公开(公告)日：2024-12-12

申请号：US18494879

申请日：2023-10-26

Applicant: RegenCELLS Biomedical Co. Ltd.

Inventor： Shih-Chen TSAI ,  Wei-Hung CHEN

IPC: C12N5/079 ,  A61K35/30 ,  C12N9/64 ,  C12N9/76 ,  C12Q1/686

Abstract: The present invention primarily relates to a method for in vitro culturing and expanding nucleus pulposus cells derived from an intervertebral disc. A secondary objective of the present invention is to provide a method for improving lower back pain by administering an effective amount of a pharmaceutical composition containing said nucleus pulposus cells obtained through the aforementioned method to subjects experiencing lower back pain.

公开(公告)号：US12161760B2

公开(公告)日：2024-12-10

申请号：US17045127

申请日：2019-03-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Lauren Emily Barney ,  Michael Beauregard ,  Guillaume Carmona ,  Francisco Caballero Gonzalez ,  Richard Heidebrecht ,  Erika Ellen Johnston ,  Robert James Miller ,  Matthias Alexander Oberli ,  Owen O'Connor ,  David Peritt ,  Jared A. Sewell ,  Devyn McKinley Smith ,  Omid Veiseh ,  Paul Kevin Wotton

IPC: A61K9/50 ,  A61K35/28 ,  A61K35/30 ,  C07K14/62 ,  C07K14/755 ,  C12N9/64

Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

公开(公告)号：US20240392276A1

公开(公告)日：2024-11-28

申请号：US18429347

申请日：2024-01-31

Applicant: AbClonal Science, Inc.

Inventor： Dapeng Sun ,  Zhenyu Zhu ,  Aine Quimby

IPC: C12N9/64

Abstract: Disclosed is using a TEV protease (wild type or mutant) suited for removal from a reaction mixture, wherein the TEV protease displays a dual affinity tag including a chitin binding domain (CBD) tag and a histidine tag, preferably where the CBD tag precedes the N-terminus of the protease and the CBD tag is preceded by the histidine tag, which is preferably a 6-mer histidine tag; and optionally further including linkers, preferably Gly-Ser linkers, and more preferably a 6-mer Gly-Ser linker, between the tags. A linker, also preferably a Gly-Ser linker, can also follow the CBD tag and precede the protease portion. In certain embodiments, no such linkers are present and in other embodiments, only one such linker is present.

公开(公告)号：US12150977B2

公开(公告)日：2024-11-26

申请号：US16877329

申请日：2020-05-18

Applicant: Phillip Douglas Kiester

Inventor： Phillip Douglas Kiester

IPC: A61K38/48 ,  A61B17/16 ,  C12N9/64 ,  A61B90/00 ,  C12N9/52

Abstract: The METHODS, APPARATUSES AND SYSTEMS FOR ADOLESCENT IDIOPATHIC SCOLIOSIS TREATMENT (hereinafter “AIST”) disclosed herein leverage the biomechanical cause of AIS in the ventral portion of the interspinous ligament to treat AIS. In various embodiments, the AIST include chemically lysing the abnormal tethering structure, thereby allowing the AIS spine to decrease its deformity with usual day-to-day activities, without bracing and without instrumented and/or fusion surgery.